ATE73331T1 - Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus. - Google Patents

Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.

Info

Publication number
ATE73331T1
ATE73331T1 AT86107614T AT86107614T ATE73331T1 AT E73331 T1 ATE73331 T1 AT E73331T1 AT 86107614 T AT86107614 T AT 86107614T AT 86107614 T AT86107614 T AT 86107614T AT E73331 T1 ATE73331 T1 AT E73331T1
Authority
AT
Austria
Prior art keywords
treatment
autism
tetrahydrobiopterins
medication
children
Prior art date
Application number
AT86107614T
Other languages
German (de)
English (en)
Inventor
Hiroshi Naruse
Masashi Takesada
Osamu Hayaishi
Yasuyoshi Watanabe
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ATE73331T1 publication Critical patent/ATE73331T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT86107614T 1985-06-04 1986-06-04 Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus. ATE73331T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP60121347A JPS61277618A (ja) 1985-06-04 1985-06-04 自閉症治療剤
EP86107614A EP0209689B1 (en) 1985-06-04 1986-06-04 Use of tetrahydrobiopterins in the preparation of a medicament for the treatment of infantile autism

Publications (1)

Publication Number Publication Date
ATE73331T1 true ATE73331T1 (de) 1992-03-15

Family

ID=14809022

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86107614T ATE73331T1 (de) 1985-06-04 1986-06-04 Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.

Country Status (5)

Country Link
US (2) US4778794A (enExample)
EP (1) EP0209689B1 (enExample)
JP (1) JPS61277618A (enExample)
AT (1) ATE73331T1 (enExample)
DE (1) DE3684190D1 (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
EP0318926B1 (en) * 1987-11-30 1995-05-03 Kabushiki Kaisha Vitamin Kenkyusyo Intermediates for synthesizing 5,6,7,8-tetrahydro-L-erythro-biopterin and its derivatives
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
ATE218345T1 (de) 1994-08-05 2002-06-15 Suntory Ltd Arzneimittel gegen spinocerebellare degeneration
ATE252385T1 (de) 1996-08-30 2003-11-15 Daiichi Suntory Pharma Co Ltd Vorbeugende oder heilende mittel für krankheiten, die durch mangel an stickoxid-synthase (nos) ausgelöst sind
US6197746B1 (en) 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
DE69830185D1 (de) * 1997-05-19 2005-06-16 Repligen Corp Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen
JP4306825B2 (ja) * 1998-02-27 2009-08-05 アスビオファーマ株式会社 インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤
WO1999043324A1 (en) * 1998-02-27 1999-09-02 Suntory Limited Preventives or remedies for drug-induced renal disturbance
AU2001253886A1 (en) * 2000-04-12 2001-10-30 Repligen Corporation Methylxanthines in the diagnosis and treatment of autistic disorder
WO2003079886A2 (en) * 2002-03-21 2003-10-02 Hinz Martin C Serotonin and catecholamine system segment optimization techonology
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
US20060110325A1 (en) * 2003-02-21 2006-05-25 Hinz Martin C Serotonin and catecholamine segment optimization technology
DE10260263A1 (de) * 2002-12-20 2004-07-15 Biocrates Life Sciences Gmbh Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
AU2012200512C1 (en) * 2003-11-17 2020-04-30 Merck & Cie Crystalline forms of (6R) -L-erythro-tetrahydrobiopterin dihydrochloride
CA2545584C (en) 2003-11-17 2012-10-23 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of metabolic disorders
EP1751312A4 (en) * 2004-05-21 2010-01-27 Univ Duke POLYMORPHISM IN TRYPTOPHAN HYDROXYLASE 2 REGULATING BRAIN SEROTONIN SYNTHESIS
AU2005259961B2 (en) * 2004-06-25 2012-05-17 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
JP2008520574A (ja) * 2004-11-17 2008-06-19 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンの安定性錠剤処方物
JP2008523090A (ja) * 2004-12-08 2008-07-03 バイオマリン ファーマシューティカル インコーポレイテッド 新生児肺高血圧症の治療のための方法および組成物
US20070034214A1 (en) * 2005-08-12 2007-02-15 Dochniak Michael J Method to affect the development of autism spectrum disorders
JP2009518415A (ja) * 2005-12-05 2009-05-07 バイオマリン ファーマシューティカル インコーポレイテッド 疾患の処置のための方法および組成物
JPWO2007119367A1 (ja) * 2006-03-20 2009-08-27 株式会社カネカ ビオプテリンを含む組成物及びその使用方法
US20100009997A1 (en) * 2007-01-12 2010-01-14 Biomarin Pharmaceutical Inc. Method of treating a metabolic or neuropsychiarty disorder with a bh4 derivative prodrug
CA2675134A1 (en) * 2007-01-12 2008-07-24 Biomarin Pharmaceutical Inc. Pterin analogs
ES2397746T3 (es) 2007-04-11 2013-03-11 Biomarin Pharmaceutical Inc. Métodos de administración de tetrahidrobiopterina, composiciones asociadas y métodos de medición
EP2224927B1 (en) 2008-01-03 2014-08-20 BioMarin Pharmaceutical Inc. Pterin analog for treating bh4 responsive condition
US20110104074A1 (en) * 2008-06-18 2011-05-05 University Of Louisville Research Foundation, Inc. Methods for targeted cancer treatment and detection
JP2011530540A (ja) * 2008-08-12 2011-12-22 オルファ スイス ゲーエムベーハー テトラヒドロビオプテリンを含有する医薬剤形
JP5066756B2 (ja) * 2010-04-22 2012-11-07 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
ES2703255T3 (es) 2010-10-22 2019-03-07 Univ Duke Formulaciones de liberación lenta de 5-hidroxitriptófano como un complemento para terapias pro-serotoninérgicas
EP2680848A4 (en) * 2011-03-01 2014-11-05 Rubicon Res Private Ltd STABLE TETRAHYDROBIOPTERINE COMPOSITIONS
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
EP2847158A4 (en) 2012-05-07 2015-12-30 Cellix Bio Private Ltd COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS AND NEURODEGENERATIVE DISORDERS
CN104350041A (zh) 2012-05-07 2015-02-11 塞利克斯比奥私人有限公司 用于治疗神经系统疾病的组合物和方法
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
CA2873098A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9765020B2 (en) 2012-05-23 2017-09-19 Cellix Bio Private Limited Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
WO2013175357A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of inflammatory bowel disease
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
CN104364231A (zh) 2012-09-08 2015-02-18 塞利克斯比奥私人有限公司 用于治疗炎症和脂质异常的组合物和方法
WO2014041446A2 (en) * 2012-09-17 2014-03-20 Mahesh Kandula Compositions and methods for the treatment of metabolic diseases
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
WO2015034984A1 (en) * 2013-09-05 2015-03-12 Emory University Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための組成物及び方法
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN110845355A (zh) 2015-01-06 2020-02-28 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法
WO2017015049A1 (en) 2015-07-17 2017-01-26 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US11464756B1 (en) 2017-05-19 2022-10-11 Jerry Darm Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8318833D0 (en) * 1983-07-12 1983-08-10 Wellcome Found Chemical compounds
JPS5976086A (ja) * 1982-09-20 1984-04-28 ザ　ウエルカム　フアウンデ−シヨン　リミテツド プテリジン化合物
DK426083A (da) * 1982-09-20 1984-03-21 Wellcome Found Pteriner, fremgangsmaader til deres fremstilling samt deres anvendelse

Also Published As

Publication number Publication date
EP0209689B1 (en) 1992-03-11
DE3684190D1 (de) 1992-04-16
JPH0380127B2 (enExample) 1991-12-24
EP0209689A3 (en) 1989-12-20
JPS61277618A (ja) 1986-12-08
US4778794A (en) 1988-10-18
EP0209689A2 (en) 1987-01-28
US4920122A (en) 1990-04-24

Similar Documents

Publication Publication Date Title
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
UA41297C2 (uk) Похідні індолу, фармацевтична композиція і спосіб лікування
ATE227587T1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE68923819D1 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
ATE122885T1 (de) Mittel zur behandlung von herzerkrankungen.
ATE142877T1 (de) Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
DE3855113D1 (de) Verwendung von Buspiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung der Alkoholsucht
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
ATE206914T1 (de) Verwendung von ursolsäure zur herstellung eines arzneimittels zur unterdrückung von metastasen
ES8102141A1 (es) Un procedimiento para preparar compuestos de acido 3-cefem-4-carboxilico disustituido en las posiciones 3 y 7
DE3850154D1 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69129563D1 (de) Epidermis-Wachstumsfaktor als Arzneimittel zur Wiederherstellung der Neuronen der Substantia nigra in der Behandlung nervenzerstörender Störungen
ATE110568T1 (de) Pharmazeutisches präparat zur behandlung des katarakts.
ATE181503T1 (de) Verwendung von idazoxan und derivaten zur herstellung eines arzneimittels zur behandlung von parkinsonismus und seiner evolution
ATE192650T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE24834T1 (de) Verwendung von beta-(1-adamantyl)-alpha, alphadimethylethylamin zur herstellung eines arzneimittels zur behandlung von otitis externa bei hunden.
DE3584426D1 (de) Verwendung von spergualin oder eines seiner pharmazeutisch akzeptablen salze zur herstellung eines transplantation-immunitaet unterdrueckenden und anti-allergischen mittels.
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.
DE59107405D1 (de) Ein Imidazobenzodiazepin zur Behandlung von Schlafstörungen
ATE72397T1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
ATE136776T1 (de) Verwendung von heptastigmin zur behandlung der zerebralen ictus
DE3884878D1 (de) Uricosuretische Zusammensetzung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee